Skip to main content
Trials
Sponsors
Conditions
Drugs
Pricing
Trials
Sponsors
Conditions
Drugs
Pricing
Loading search results
Clinical Trials for "David A Rizzieri, MD"
9
trials
Share
Relevance
ID
Status
Phase
Title
Sponsor
NCT00004143
Completed
Phase 2
Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes
David Rizzieri, MD
ClinicalTrials.gov
NCT00004143
Completed
Phase 2
Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopat...
David Rizzieri, MD
NCT00511043
Terminated
Phase 2
PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma
David Rizzieri, MD
ClinicalTrials.gov
NCT00511043
Terminated
Phase 2
PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma
David Rizzieri, MD
NCT00578942
Completed
Phase 2
Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath
David Rizzieri, MD
ClinicalTrials.gov
NCT00578942
Completed
Phase 2
Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Usi...
David Rizzieri, MD
NCT00580034
Completed
Phase 2
Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath
David Rizzieri, MD
ClinicalTrials.gov
NCT00580034
Completed
Phase 2
Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged...
David Rizzieri, MD
NCT00586690
Completed
Phase 1
Safety Trial of NK DLI From 6/6 HLA Matched Family Member Following Nonmyeloablative ASCT
David Rizzieri, MD
ClinicalTrials.gov
NCT00586690
Completed
Phase 1
Safety Trial of NK DLI From 6/6 HLA Matched Family Member Following Nonmyeloabla...
David Rizzieri, MD
NCT00586703
Completed
Phase 1
Safety Trial of NK Cell DLI 3-5/6 Family Member Following Nonmyeloablative ASCT
David Rizzieri, MD
ClinicalTrials.gov
NCT00586703
Completed
Phase 1
Safety Trial of NK Cell DLI 3-5/6 Family Member Following Nonmyeloablative ASCT
David Rizzieri, MD
NCT00597714
Completed
Phase 2
Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant
David Rizzieri, MD
ClinicalTrials.gov
NCT00597714
Completed
Phase 2
Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transpl...
David Rizzieri, MD
NCT01373229
Completed
Phase 1
Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)
Celgene Corporation
ClinicalTrials.gov
NCT01373229
Completed
Phase 1
Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CL...
Celgene Corporation
NCT02115126
Withdrawn
Phase 2
Phase II Trial to Evaluate an EBV-derived Dendritic Cell Vaccine in Autologous Stem Cell Transplant
David Rizzieri, MD
ClinicalTrials.gov
NCT02115126
Withdrawn
Phase 2
Phase II Trial to Evaluate an EBV-derived Dendritic Cell Vaccine in Autologous S...
David Rizzieri, MD
Result Breakdown
Status
Completed
7 (78%)
Terminated
1 (11%)
Withdrawn
1 (11%)
Phase
Phase 2
6 (67%)
Phase 1
3 (33%)
Top Conditions
Lymphoma
4 (44%)
Leukemia
3 (33%)
Myelodysplasia
3 (33%)
Show 7 more
Top Sponsors
David Rizzieri, MD
9 (100%)
Miltenyi Biomedicine GmbH
2 (22%)
Novartis Pharmaceuticals
1 (11%)
Show 2 more
Start your search
Search over 500,000 clinical trials worldwide
Search
Expert
Popular:
Cancer
Diabetes
Alzheimer
COVID-19
Heart Disease